drugset / Trial / NCT03608371
BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations
RandomizedSequentialQuadruple-blindTreatment
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and efficacy of BTRX-246040 in participants with Parkinson's Disease who have motor fluctuations and predictable early morning off periods.
Timeline
- Start
- 2018-08-31
- Primary completion
- 2019-04-16
- Completion
- 2019-04-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2940094 | Small molecule | 40 mg | Oral |
| Subject | LY2940094 | Small molecule | 80 mg | Oral |
| Subject | LY2940094 | Small molecule | 120 mg | Oral |